



(51) International Patent Classification:

C12N 5/0783 (2010.01) A61P 37/00 (2006.01)
A61K 35/17 (2014.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/063457

(22) International Filing Date:

04 December 2020 (04.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/945,040 06 December 2019 (06.12.2019) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];
3535 General Atomics Court, Suite 200, San Diego, CA
92121 (US).

(72) Inventors: **VALAMEHR, Bahram**; 3535 General Atomics
Court, Suite 200, San Diego, CA 92121 (US). **BJOR-**
DAHL, Ryan; 3535 General Atomics Court, Suite 200, San
Diego, CA 92121 (US). **GOODRIDGE, Jode**; 3535 General
Atoms Court, Suite 200, San Diego, CA 92121 (US).
MANDAL, Mili; 3535 General Atomics Court, Suite 200,
San Diego, CA 92121 (US). **CHANG, Chia-Wei**; 3535

General Atomics Court, Suite 200, San Diego, CA 92121
(US).


(74) Agent: **GIERING, Jeffery, C.** et al.; Mintz Levin Cohn
Ferris Glovsky and Popeo, P.C., One Financial Center,
Boston, MA 02111 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ENHANCEMENT OF IPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS

FIG. 2A



(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*